Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum

ISBN-13: 9783031335358 / Angielski

Vikas Prasad

Spis treści

1.            Molecular Radiotherapy: Overcoming resistance; Johannes Czernin

2.            Evolving Role of Nuclear Medicine in Multi-Disciplinary Care at MD Anderson; Homer Macapinlac

3.            Goethe’s Genomic Reflections on Baum - Grau ist alle Theorie; Irvin Modlin

4.            The Lugenium Triptych: Ode to a Theranostics Transcriptome; Lisa Bodei

5.            Theranostics with somatostatin receptor antagonists.; Damian Wild

6.            The times they are a´ changing: Radiometal-theranostics from 86Y/90Y to 68Ga/177Lu and beyond; Frank Rösch

7.            Real-World Evidence: Clinical Outcomes In Precision Radionuclide Oncology. The WARMTH NIGHTCAP Study of 177Lu-PSMA in Metastatic Prostate Cancer.; J. Harvey Turner

8.            Combining surgery with peptide receptor radionuclide therapy – a step forward in treatment of advanced neuroendocrine tumours; Andrea Frilling

9.            Terbium “Sisters”: More than just a “Swiss Army Knife”; Cristina Müller

10.          'PSMA Radioligand Therapy - A Revolution in the Precision Oncology of Prostate Cancer'; Harshad Kulkarni

11.          Nuclear medicine and surgery a new productive new marriage; Daniel Kämmerer

12.          'Sola dosis facit venenum: Dosimetrie in Precision Oncology with Radiolabelled Probe'; Christiane Schuchardt

13.          Random Walk in Nuclear Medicine - How a Chance Meeting Changed the Course of NET Patient Care in the US; Josh Mailman

14.          Theranostic Radiopeptides in Nuclear Oncology: Design, Preclinical Screening & Clinical Translation; Theodosia Maina

15.          Ac-225 PSMA in metastatic prostate cancer without previous chemotherapy; Mike Sathekge

16.          Following the co-evolution of Innovation and demand in the field of precision oncology; Konstantin Zhernosekov, Sebastian Marx

17.          milestone of therapies in NEN; Mariane Pavel

18.          Impact of Radioimmunodetection and Radioimmunotherapy on Theranostics and Antibody-targeted Therapies; David Goldenberg

19.          Molecular imaging platform and radiopharmaceutical transnational research on  Peking University  Cancer Hospital; Zhi Yang

20.          Radioiodine labeled metaiodobenzylguanidine for imaging and treatment of the adrenal medulla and extra-adrenal paraganglia tumors; Manfred Fischer

21.          WARMTH History; Savvas Frangos

22.          How to improve personalised / individualised medicine in 2030; Bertram Wiedenmann

23.          Real Precision Radionuclide Therapy; Ralph  McCready

24.          How do you feel about dosimetry?" The Gretchenfrage of Radionuclide Therapy; Matthias Blaickner

25.          High-Performance Radiopharmacy - The Base for Precision Oncology; Dirk Müller

26.          The Rise of A Theranostic Empire: Good Governance and Precision Oncology; Vikas Prasad

27.          Peptide Radiochemistry In Precision Oncology Redefined: Integration of Standard Quality Control in GMP Radiochemistry with State of the Art mass Spectrometry; Sonal Prasad

28.          Dose it possible to targeting HER2 using Affibody receptor radionuclide therapy; Hua Zhu

29.          Precision Oncology with PSMA-targeted Alpha Particle Therapy of mCRPC; Jadvar Hossein

30.          18 FDG PET CT assessing Inmunotherapy response; Mariela Agolti

31.          PSMA targeted imaging and therapy with radiolabeled antibodies and peptides; Shankar Vallabhajoshula

32.          Combining targeted radiation therapies in modern clinical oncological practice; Nat Lenzo

33.          From Concept to Clinic and Comercialisation  - Cowboys Wanted; Christian Behrenbruch

34.          Cardiotoxicity of targeted therapies: Imaging of Heart Does Matter; Marcus Hacker

35.          International prostate cancer PSMA RLT trials; Bernd Krause

36.          Fighting for PET in German oncological guidelines and for its reimbursement by Statutory Health Insurances; Dirk Hellwig

37.          CXCR4 Theranostic Experience from India; Baljinder Singh

38.          From Radioimmunodetection to Radiomolecular Precision Oncology via Radionanotargeting  by Intelligent Multidisciplinary Radiotheragnostic Nanoparticles; Kalevi Kairemo

39.          theranostic pair 203Pb and 212Pb for image-guided alpha/beta particle therapy for cancer.; Michael Schultz

40.          Dosing schedule of PSMA: Adaptation in RLT is the key to success against mCRPC; Alexander Haug

41.          Radioiodine labeled metaiodobenzylguanidine for imaging and treatment of the adrenal medulla and extra-adrenal paraganglia tumors; Matthias Schmidt

42.          Theranostics of Hodgkins disease Does it have a future?; John Buscombe

43.          Radioligand Therapy of Thyroid cancer: A Revolution in Evolution; Michael Kreißl

44.          Somatostatin at its receptor the birth of Theranostics; Kjell Öberg

45.          making sure theranostics stays in nuclear medicine; Ken Herrmann

46.          Molecular in-vitro & in-vivo diagnostics as the impartible basis of multimodal therapy approaches in precision oncology; Ralph M Wirtz

47.          precision oncology with radiolabelled compounds" based on the example : in vitro and in vivo correlation; Maria Athelogou

O autorze

Prof. Dr. Vikas Prasad, 

Director Clinical Theranostics, Associate Professor of Radiology

Division of Nuclear Medicine, Mallinckrodt Institute of Radiology

Washington University in Saint Louis

Saint Louis, Missouri, USA

Blurb

This open access book is written by world-renowned experts on radiomolecular precision oncology to celebrate the work, life, principles and ideology of Richard P. Baum.
It includes commentaries, reviews and some thought provoking novel ideas on radionuclide precision oncology, covering topics such as various aspects of theranostics and molecular radiotherapy like radiolabeled peptides, radiolabeled antibodies, dosimetry, and quality control as well as the diagnosis and treatment of specific tumor types. Featuring contributions by biologists, physicists, chemists, mathematicians, geneticists, and physicians from a range of specialties, this Festschrift is highly interdisciplinary and will be a valuable resource for future precision oncologists.